# OnCo record nct03907852 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03907852/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03907852", "NCT03907852" ;
  schema:name "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer"@en ;
  schema:description "A phase 1/2 trial of Fludarabine, Cyclophosphamide, Nivolumab in mesothelioma and ovarian cancer, run by TCR2 Therapeutics, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03907852/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03907852> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2019-04-15" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:drugs <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct03907852-nat-med-2023/> .